Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma

Shawn D. Safford, R. Edward Coleman, Jon P. Gockerman, Joseph Moore, Jerome M. Feldman, George S. Leight, Douglas Tyler, John A. Olson, Robert Udelsman, Ashok R. Shaha, Ronald J. Weigel, Geoffrey B. Thompson

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Introduction. Iodine 131-meta-iodobenzylguanidine (131I-MIBG) has been applied to the palliative treatment of metastatic pheochromocytoma in small studies. We report our institutional experience for the treatment of metastatic pheochromocytoma and paraganglioma. Methods. We performed a retrospective review of 33 patients with metastatic pheochromocytoma (n = 22) and paraganglioma (n = 11) treated at our institution with 131I-MIBG over a 10-year period. Results. Patients received a mean dose of 388 ± 131 mCi 131I-MIBG. Median survival after treatment was 4.7 years. Most patients experienced a symptomatic response leading to an improved survival (4.7 years vs 1.8 years, P < .01). Patients with a measurable hormone response demonstrated an increased survival in comparison to those with no response (4.7years vs 2.6years, P = .01). Patients who received a high dose (>500 mCi) as their initial therapy also had improved survival (3.8 years vs 2.8 years, P = .02). Conclusion. These data support 131I-MIBG treatment for select patients with metastatic pheochromocytoma. In our experience, prolonged survival was best predicted by symptomatic and hormone response to 131I-MIBG treatment. An initial dose of 500 mCi may be optimal The benefit of 131I-MIBG treatment for metastatic pheochromocytoma must also be weighed against its side effects.

Original languageEnglish (US)
Pages (from-to)956-963
Number of pages8
JournalSurgery
Volume134
Issue number6
DOIs
StatePublished - Dec 2003
Externally publishedYes

Fingerprint

3-Iodobenzylguanidine
Paraganglioma
Pheochromocytoma
Iodine
Survival
Therapeutics
Palliative Care
Hormones

ASJC Scopus subject areas

  • Surgery

Cite this

Safford, S. D., Coleman, R. E., Gockerman, J. P., Moore, J., Feldman, J. M., Leight, G. S., ... Thompson, G. B. (2003). Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery, 134(6), 956-963. https://doi.org/10.1016/S0039-6060(03)00426-4

Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. / Safford, Shawn D.; Coleman, R. Edward; Gockerman, Jon P.; Moore, Joseph; Feldman, Jerome M.; Leight, George S.; Tyler, Douglas; Olson, John A.; Udelsman, Robert; Shaha, Ashok R.; Weigel, Ronald J.; Thompson, Geoffrey B.

In: Surgery, Vol. 134, No. 6, 12.2003, p. 956-963.

Research output: Contribution to journalArticle

Safford, SD, Coleman, RE, Gockerman, JP, Moore, J, Feldman, JM, Leight, GS, Tyler, D, Olson, JA, Udelsman, R, Shaha, AR, Weigel, RJ & Thompson, GB 2003, 'Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma', Surgery, vol. 134, no. 6, pp. 956-963. https://doi.org/10.1016/S0039-6060(03)00426-4
Safford, Shawn D. ; Coleman, R. Edward ; Gockerman, Jon P. ; Moore, Joseph ; Feldman, Jerome M. ; Leight, George S. ; Tyler, Douglas ; Olson, John A. ; Udelsman, Robert ; Shaha, Ashok R. ; Weigel, Ronald J. ; Thompson, Geoffrey B. / Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. In: Surgery. 2003 ; Vol. 134, No. 6. pp. 956-963.
@article{d29c4faa87e043a6b7f020308092cf66,
title = "Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma",
abstract = "Introduction. Iodine 131-meta-iodobenzylguanidine (131I-MIBG) has been applied to the palliative treatment of metastatic pheochromocytoma in small studies. We report our institutional experience for the treatment of metastatic pheochromocytoma and paraganglioma. Methods. We performed a retrospective review of 33 patients with metastatic pheochromocytoma (n = 22) and paraganglioma (n = 11) treated at our institution with 131I-MIBG over a 10-year period. Results. Patients received a mean dose of 388 ± 131 mCi 131I-MIBG. Median survival after treatment was 4.7 years. Most patients experienced a symptomatic response leading to an improved survival (4.7 years vs 1.8 years, P < .01). Patients with a measurable hormone response demonstrated an increased survival in comparison to those with no response (4.7years vs 2.6years, P = .01). Patients who received a high dose (>500 mCi) as their initial therapy also had improved survival (3.8 years vs 2.8 years, P = .02). Conclusion. These data support 131I-MIBG treatment for select patients with metastatic pheochromocytoma. In our experience, prolonged survival was best predicted by symptomatic and hormone response to 131I-MIBG treatment. An initial dose of 500 mCi may be optimal The benefit of 131I-MIBG treatment for metastatic pheochromocytoma must also be weighed against its side effects.",
author = "Safford, {Shawn D.} and Coleman, {R. Edward} and Gockerman, {Jon P.} and Joseph Moore and Feldman, {Jerome M.} and Leight, {George S.} and Douglas Tyler and Olson, {John A.} and Robert Udelsman and Shaha, {Ashok R.} and Weigel, {Ronald J.} and Thompson, {Geoffrey B.}",
year = "2003",
month = "12",
doi = "10.1016/S0039-6060(03)00426-4",
language = "English (US)",
volume = "134",
pages = "956--963",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma

AU - Safford, Shawn D.

AU - Coleman, R. Edward

AU - Gockerman, Jon P.

AU - Moore, Joseph

AU - Feldman, Jerome M.

AU - Leight, George S.

AU - Tyler, Douglas

AU - Olson, John A.

AU - Udelsman, Robert

AU - Shaha, Ashok R.

AU - Weigel, Ronald J.

AU - Thompson, Geoffrey B.

PY - 2003/12

Y1 - 2003/12

N2 - Introduction. Iodine 131-meta-iodobenzylguanidine (131I-MIBG) has been applied to the palliative treatment of metastatic pheochromocytoma in small studies. We report our institutional experience for the treatment of metastatic pheochromocytoma and paraganglioma. Methods. We performed a retrospective review of 33 patients with metastatic pheochromocytoma (n = 22) and paraganglioma (n = 11) treated at our institution with 131I-MIBG over a 10-year period. Results. Patients received a mean dose of 388 ± 131 mCi 131I-MIBG. Median survival after treatment was 4.7 years. Most patients experienced a symptomatic response leading to an improved survival (4.7 years vs 1.8 years, P < .01). Patients with a measurable hormone response demonstrated an increased survival in comparison to those with no response (4.7years vs 2.6years, P = .01). Patients who received a high dose (>500 mCi) as their initial therapy also had improved survival (3.8 years vs 2.8 years, P = .02). Conclusion. These data support 131I-MIBG treatment for select patients with metastatic pheochromocytoma. In our experience, prolonged survival was best predicted by symptomatic and hormone response to 131I-MIBG treatment. An initial dose of 500 mCi may be optimal The benefit of 131I-MIBG treatment for metastatic pheochromocytoma must also be weighed against its side effects.

AB - Introduction. Iodine 131-meta-iodobenzylguanidine (131I-MIBG) has been applied to the palliative treatment of metastatic pheochromocytoma in small studies. We report our institutional experience for the treatment of metastatic pheochromocytoma and paraganglioma. Methods. We performed a retrospective review of 33 patients with metastatic pheochromocytoma (n = 22) and paraganglioma (n = 11) treated at our institution with 131I-MIBG over a 10-year period. Results. Patients received a mean dose of 388 ± 131 mCi 131I-MIBG. Median survival after treatment was 4.7 years. Most patients experienced a symptomatic response leading to an improved survival (4.7 years vs 1.8 years, P < .01). Patients with a measurable hormone response demonstrated an increased survival in comparison to those with no response (4.7years vs 2.6years, P = .01). Patients who received a high dose (>500 mCi) as their initial therapy also had improved survival (3.8 years vs 2.8 years, P = .02). Conclusion. These data support 131I-MIBG treatment for select patients with metastatic pheochromocytoma. In our experience, prolonged survival was best predicted by symptomatic and hormone response to 131I-MIBG treatment. An initial dose of 500 mCi may be optimal The benefit of 131I-MIBG treatment for metastatic pheochromocytoma must also be weighed against its side effects.

UR - http://www.scopus.com/inward/record.url?scp=10744221975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744221975&partnerID=8YFLogxK

U2 - 10.1016/S0039-6060(03)00426-4

DO - 10.1016/S0039-6060(03)00426-4

M3 - Article

VL - 134

SP - 956

EP - 963

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 6

ER -